Drug Profile
EMD 1204831
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator EMD Serono; Merck Serono
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 09 Jan 2012 Discontinued - Phase-I for Solid tumours in USA (unspecified route)
- 19 Apr 2010 Phase-I clinical trials of monotherapy in late-stage Solid tumours in USA (unspecified route)